Liane Rae Teplitsky Buys 1,001 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Teplitsky purchased 1,001 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were purchased at an average price of $49.95 per share, for a total transaction of $49,999.95. Following the purchase, the chief operating officer directly owned 4,095 shares in the company, valued at $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Liane Rae Teplitsky also recently made the following trade(s):

• On Monday, August 31st, Liane Teplitsky acquired 1,024 shares of Pulse Biosciences stock. The stock was purchased at an average price of $48.80 per share, with a total value of $49,971.20.
• On Friday, August 28th, Liane Teplitsky acquired 1,034 shares of Pulse Biosciences stock. The stock was purchased at an average cost of $48.35 per share, with a total value of $49,993.90.
• On Wednesday, August 26th, Liane Teplitsky acquired 1,036 shares of Pulse Biosciences stock. The stock was purchased at an average cost of $48.23 per share, with a total value of $49,966.28.

Pulse Biosciences Trading Up 3.9%

Shares of PLSE opened at $54.71 on Friday. The firm has a market cap of $3.79 billion, a PE ratio of -46.36 and a beta of 1.63. The company’s 50 day simple moving average is $37.48 and its 200-day simple moving average is $27.82. Pulse Biosciences, Inc has a 12-month low of $12.56 and a 12-month high of $55.37.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. As a group, equities research analysts forecast that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on PLSE. Canaccord Genuity Group increased their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Needham & Company LLC assumed coverage on Pulse Biosciences in a report on Monday, August 17th. They set a “buy” rating and a $58.00 price target on the stock. Mizuho set a $45.00 price target on Pulse Biosciences in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pulse Biosciences presently has an average rating of “Moderate Buy” and an average price target of $45.25.

Hedge Funds Weigh In On Pulse Biosciences

Several institutional investors have recently bought and sold shares of PLSE. BlackRock Inc. acquired a new stake in shares of Pulse Biosciences in the 2nd quarter worth $40,672,000. Bank of America Corp DE acquired a new position in shares of Pulse Biosciences during the second quarter worth about $40,115,000. California State Teachers Retirement System raised its holdings in Pulse Biosciences by 2,600.0% during the second quarter. California State Teachers Retirement System now owns 567,883 shares of the company’s stock worth $15,747,000 after purchasing an additional 546,850 shares in the last quarter. State Street Corp raised its holdings in Pulse Biosciences by 6.0% during the fourth quarter. State Street Corp now owns 447,067 shares of the company’s stock worth $6,138,000 after purchasing an additional 25,187 shares in the last quarter. Finally, Brooklyn Investment Group lifted its position in Pulse Biosciences by 330.7% in the fourth quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock valued at $1,844,000 after purchasing an additional 100,081 shares during the period. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.